Get started
Author

Antony Constantinou

Towards Controlling the Glycoform: A Model Framework Linking Extracellular Metabolites to Antibody Glycosylation
2014 · Philip Jedrzejewski, Ioscani Del Val, et al. · International Journal of Molecular Sciences · 86
PDF
Modulation of Antibody Pharmacokinetics by Chemical Polysialylation
2008 · Antony Constantinou, Agamemnon A. Epenetos, et al. · Bioconjugate Chemistry · 65
Site-Specific Polysialylation of an Antitumor Single-Chain Fv Fragment
2009 · A. Constantinou, A. A. Epenetos, et al. · Bioconjugate Chemistry · 62
Modulating the pharmacokinetics of therapeutic antibodies
2010 · A. Constantinou, C. Chen, et al. · Biotechnology Letters · 58
Modulating antibody pharmacokinetics using hydrophilic polymers
2011 · Chen Chen, Antony Constantinou, et al. · Expert Opinion on Drug Delivery · 49
Glycoengineering Approach to Half-Life Extension of Recombinant Biotherapeutics
2012 · Chen Chen, Antony Constantinou, et al. · Bioconjugate Chemistry · 37
Opportunities for bioprocess monitoring using FRET biosensors
2013 · Antony Constantinou, Karen M. Polizzi · Biochemical Society Transactions · 18
A 5.9-kb tandem repeat at the euchromatin-heterochromatin boundary of the X chromosome of Drosophila melanogaster
2002 · K. O'Hare, B. Chadwick, et al. · Molecular Genetics and Genomics · 10
A quantitative and mechanistic model for monoclonal antibody glycosylation as a function of nutrient availability during cell culture
2013 · Ioscani Jiménez del Val, Antony Constantinou, et al. · BMC Proceedings · 9
PDF
Polysialic Acid and Polysialylation to Modulate Antibody Pharmacokinetics
2012 · Antony Constantinou, Chen Chen, et al. · Wiley eBooks · 8
Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al. · Molecular Cancer Therapeutics · 5
FIBS-enabled Noninvasive Metabolic Profiling
2014 · Alireza Behjousiar, Antony Constantinou, et al. · Journal of Visualized Experiments · 1
Supplementary Figure 4 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Data from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 1 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 9 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Table 2 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Table 4 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Table 1 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 2 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 7 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 5 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 10 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Table 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Works count: 32
Citation count: 408
H-index: 9
I10-index: 8
Year
Topic
Type